Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08 Mai 2024 - 5:31PM
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members,
executives and associated persons
Bagsværd, Denmark, 8 May 2024 — This company
announcement discloses the data of the transaction(s) made in Novo
Nordisk shares by the company’s board members, executives and their
associated persons in accordance with Article 19 of Regulation No.
596/2014 on market abuse.
The company’s board members, executives and their associated
persons have reported the transactions to Novo Nordisk and have
given Novo Nordisk power of attorney on their behalf to publish
trading in Novo Nordisk shares by the company’s board members,
executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
|
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name of the Board member/Executive/Associated Person |
Maziar Mike Doustdar |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Executive Vice President |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
4 |
Details of the transaction(s) |
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
Identification code |
Novo Nordisk B DK0062498333 |
|
b) |
Nature of the transaction |
Gift made |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
DKK 0.00 |
100 shares |
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
100 sharesDKK 0.00 |
|
e) |
Date of the transaction |
2024-05-07 |
|
f) |
Place of the transaction |
Outside a trading venue |
|
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 63,400 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contacts for further information
Media: |
|
Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Liz
Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com |
Investors: |
|
Daniel
Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com |
Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
Sina
Meyer +45 3079 6656 azey@novonordisk.com |
Frederik
Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
Ida
Melvold Gjøsund+45 3077 5649 idmg@novonordisk.com |
|
Company announcement No 40 / 2024
Novo Nordisk (TG:NOV)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Novo Nordisk (TG:NOV)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024